Skip to main content
SpringerLink
Log in

Living Donor Liver Transplantation for Hepatocellular Carcinoma

  • Chapter
  • First Online:
Multidisciplinary Treatment of Hepatocellular Carcinoma

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 190))

Abstract

Liver transplantation (LT) may be the best curative treatment that offers a chance of cure for the tumor and the underlying cirrhosis by complete extirpation of both. In Asia, where the supply of cadaveric grafts remains scarce and the incidence of HCC combined with chronic hepatitis B virus (HBV)- and hepatitis C virus (HCV)-related liver disease is high, adult living donor liver transplantation (LDLT) has been settled upon as a practical alternative to deceased-donor liver transplantation (DDLT). Even in Western countries, where adequate access to DDLT is feasible for HCC patients satisfying the Milan criteria, the necessity for LDLT is well established in particular for more advanced HCC patients who are disadvantaged by current allocation algorithms for grafts from deceased donors due to organ shortage, increasing waiting lists, and the expectation that many patients listed for LT will die while awaiting a suitable organ. In the field of LDLT in Asia, numerous technical innovations were achieved to secure donor safety, as well as to ensure patient survival. The experience with LDLT for HCC has been progressively increasing in many Asian countries to date. Although there are questions regarding the higher recurrence of HCC after LDLT than after DDLT, the application of the Milan and UCSF criteria to LDLT in high-volume multicenter cohorts from Japan and Korea has resulted in patient survival outcomes very similar to those following DDLT. Recently, inclusion of biologic tumor markers such as alpha fetoprotein (AFP), protein induced by vitamin K antagonist II (PIVKA II), and positive positron emission tomography (PET) in addition to parameters of tumor morphology might be the key to establishing the best criteria for LDLT for HCC. As pretransplant treatments, most LDLT centers in Asia cannot adopt the strategy of bridging therapy under scarcity of cadaveric organ donation but have to use those multi-modality treatments as a salvage intending for primary curative treatment or a downstaging therapy before LDLT. After LDLT, basically there is no difference in the management strategy for HCC recurrence between DDLD and LDLT.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 179.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 229.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 229.00
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

HCC:

Hepatocellular carcinoma

LT:

Liver transplantation

LDLT:

Living donor liver transplantation

DDLT:

Deceased-donor liver transplantation

MELD:

Model of end-stage liver disease

ELTR:

European Liver Transplant Registry

UCSF:

University of California, San Francisco

AFP:

Alpha fetoprotein

PIVKA II:

Protein induced by vitamin K antagonist II

18F-FDG-PET:

Positron emission tomography using 18F-fluorodeoxyglucose

CT:

Computed tomography scan

AA2LL:

Adult-to-Adult Living donor liver transplantation

References

  1. Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362:1907–1917

    Article  PubMed  Google Scholar 

  2. Song TJ, Ip EW, Fong Y (2004) Hepatocellular carcinoma: current surgical management. Gastroenterology 127(suppl 1):S248–S260

    Article  PubMed  Google Scholar 

  3. Mazzaferro V, Regalia E, Doci R et al (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693–699

    Article  PubMed  CAS  Google Scholar 

  4. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A et al (2001) Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33:1394–1403

    Article  PubMed  CAS  Google Scholar 

  5. Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP (2007) Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 7:2587–2596

    Article  PubMed  CAS  Google Scholar 

  6. Kaihara S, Kiuchi T, Ueda M et al (2003) Living-donor liver transplantation for hepatocellular carcinoma. Transplantation 75:S37–S40

    Article  PubMed  Google Scholar 

  7. Shimada M, Fujii M, Morine Y et al (2005) Living-donor liver transplantation: present status and future perspective. J Med Invest 52:22–32

    Article  PubMed  Google Scholar 

  8. Kulik L, Abecassis M (2004) Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology 127:S277–S282

    Article  PubMed  Google Scholar 

  9. Vitale A et al (2010) Estimation of the harm to the waiting list as a crucial factor in the selection of patients with hepatocellular carcinoma for liver transplantation. Transplant Proc 42:1194–1196

    Article  PubMed  CAS  Google Scholar 

  10. Fisher RA, Kulik LM, Freise CE, Lok AS, Shearon TH, Brown RS et al (2007) Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant 7:1601–1608

    Article  PubMed  CAS  Google Scholar 

  11. Hwang S, Lee SG, Lee YJ et al (2006) Lessons learned from 1,000 living donor liver transplantations in a single center: how to make living donations safe. Liver Transpl 12:920–927

    Article  PubMed  Google Scholar 

  12. Lo CM (2003) Complications and long-term outcome of living liver donors: a survey of 1,508 cases in five Asian centers. Transplantation 75:S12–S15

    Article  PubMed  Google Scholar 

  13. Hsu HT, Hwang SL, Lee PH et al (2006) Impact of liver donation on quality of life and physical and psychological distress. Transplant Proc 38:2102–2105

    Article  PubMed  Google Scholar 

  14. de Villa V, Lo CM (2007) Liver transplantation for hepatocellular carcinoma in Asia. Oncologist 12(11):1321–1331

    Article  PubMed  Google Scholar 

  15. Lee SG, Ahn CS, Ha TY, Moon DB, Choi KM, Song GW et al (2010) Liver transplantation for hepatocellular carcinoma: Korean experience. J Heaptobiliary Pancreat Sci 17:539–547

    Article  Google Scholar 

  16. Rosemurgy A et al (2008) Frequency with which surgeons undertake pancreaticoduodenectomy continues to determine length of stay, hospital charges, and in-hospital mortality. J Gastrointest Surg 12:442–449

    Article  PubMed  Google Scholar 

  17. Poon RT, Fan ST, Lo CM, Liu CL, Wong J (2007) Difference in tumor invasiveness in cirrhotic patients with hepatocellular carcinoma fulfilling the Milan criteria treated by resection and transplantation: impact on long-term survival. Ann Surg 245:51–58

    Article  PubMed  Google Scholar 

  18. Furukawa H, Shimamura T, Suzuki T, Taniguchi M, Nakanishi K, Yamashita K et al (2010) Liver transplantation for hepatocellular carcinoma: the Japanese experience. J Hepatobiliary Pancreat Sci 17:533–538

    Article  PubMed  Google Scholar 

  19. Furukawa H, Shimamura T, Suzuki T, Taniguchi M, Yamashita K, Kamiyama T et al (2006) Living-donor liver transplantation for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 13:393–397

    Article  PubMed  Google Scholar 

  20. Sarasin FP, Majino PE, Llovet JM, Bruix J, Mentha G, Hadengue A (2001) Living donor liver transplantation for early hepatocellular carcinoma: a life-expectancy and cost-effectiveness perspective. Hepatology 33:1073–1079

    Article  PubMed  CAS  Google Scholar 

  21. Cheng SJ, Pratt DS, Freeman RB Jr, Kaplan MM, Wong JB (2001) Living-donor versus cadaveric liver transplantation for non-resectable small hepatocellular carcinoma and compensated cirrhosis: a decision analysis. Transplantation 72:861–868

    Article  PubMed  CAS  Google Scholar 

  22. Lo CM, Fan ST, Liu CL, Chan SC, Wong J (2004) The role and limitation of living donor liver transplantation for hepatocellular carcinoma. Liver Transpl 10:440–447

    Article  PubMed  Google Scholar 

  23. Hwang S, Lee SG, Belghiti J (2010) Liver transplantation for HCC: its role. Eastern and Western perspectives. J Hepatobiliary Pancreat Sci 17:443–448

    Google Scholar 

  24. Lo CM, Fan ST, Liu CL et al (2007) Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma. Br J Surg 94:78–86

    Article  PubMed  CAS  Google Scholar 

  25. Todo S, Furukawa H (2004) The Japanese study group on organ transplantation. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg 240:451–459

    Article  PubMed  Google Scholar 

  26. Hwang S, Lee SG, Joh JW et al (2005) Liver transplantation for adult patients with hepatocellular arcinoma in Korea: comparison between cadaveric donor and living donor liver transplantations. Liver Transpl 11:1265–1272

    Article  PubMed  Google Scholar 

  27. Shimada M, Fujii M, Morine Y et al (2005) Living-donor liver transplantation: present status and future perspective. J Med Invest 52:22–32

    Article  PubMed  Google Scholar 

  28. Gondolesi GE, Roayaie S, Munoz L et al (2004) Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria. Ann Surg 239:142–149

    Article  PubMed  Google Scholar 

  29. Lee SG, Hwang S, Moon DB, Ahn CS, Kim KH, Sung KB et al (2008) Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl 14:935–945

    Article  PubMed  Google Scholar 

  30. Ito T, Takada Y, Ueda M et al (2007) Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. Liver Transpl 13:1637–1644

    Article  PubMed  Google Scholar 

  31. Taketomi A, Sanefuji K, Soejima Y et al (2009) Impact of des-gammacarboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation 87(4):531–537

    Article  PubMed  Google Scholar 

  32. Sugawara Y, Tamura S, Makuuchi M (2007) Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis 25:310–312

    Article  PubMed  Google Scholar 

  33. Todo S, Furukawa H, Tada M (2007) Extending indication: role of living donor liver transplantation for hepatocellular carcinoma. Liver Transpl 13(11 suppl 2):S48–S54

    Article  PubMed  Google Scholar 

  34. Ng KK, Lo CM, Chan SC, Chok KS, Cheung TT, Fan ST (2010) Liver transplantation for hepatocellular carcinoma: the Hong Kong experience. J Hepatobiliary Pancreat Sci 17:548–554

    Article  PubMed  Google Scholar 

  35. Herrero JI, Sangro B, Quiroga J, Pardo F, Herraiz M, Cienfuegos JA et al (2001) Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma. Liver Transpl 7:631–636

    Article  PubMed  CAS  Google Scholar 

  36. Yao FY, Kinkhabwala M, LaBerge JM, Bass NM, Brown R Jr et al (2005) The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant 5:795–804

    Article  PubMed  Google Scholar 

  37. Freeman RB Jr, Steffick DR, Guidinger MK, Farment DG, Berg CL, Merion RM (2008) Liver and intestine transplantation in the United States, 1997–2006. Am J Transplant 8:958–976

    Article  PubMed  Google Scholar 

  38. Belghiti J (2009) Resection and liver transplantation for HCC. J Gastroenterol 44(suppl 19):132–135

    Article  PubMed  Google Scholar 

  39. Belghiti J, Cortes A, Abdalla EK, Regimbeau JM, Prakash K, Durand F et al (2003) Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg 238:885–892

    Article  PubMed  Google Scholar 

  40. Adam R, Azoulay D, Castaing D (2003) Liver resection as a bridge to transplantation for hepatocellularcarcinoma on cirrhosis: a reasonable strategy? Ann Surg 238:508–518

    Article  PubMed  Google Scholar 

  41. Hwang S, Lee SG, Moon DB, Ahn CS, Kim KH, Lee YJ et al (2007) Salvage living donor liver transplantation after prior liver resection for hepatocellular carcinoma. Liver Transpl 13:741–746

    Article  PubMed  Google Scholar 

  42. Laurent A, Tayar C, Andreoletti M et al (2009) Laparoscopic liver resection facilitates salvage liver transplantation for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 16:310–314

    Article  PubMed  Google Scholar 

  43. Majno PE, Adam R, Bismuth H et al (1997) Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 226:688–701

    Article  PubMed  CAS  Google Scholar 

  44. Yao FY, Hirose R, LaBerge JM, Davern TJ III, Bass NM, Kerlan RK Jr et al (2005) A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl 11:1505–1514

    Article  PubMed  Google Scholar 

  45. Chapman WC, Doyle MBM, Stuart JE, Vachharajani N, Crippin JS, Anderson CD et al (2008) Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg 248:617–625

    PubMed  Google Scholar 

  46. Ravaioli M, Grazi GL, Piscaglia F, Trevisani F, Cescon M et al (2008) Liver transplantation for hepatocellular carcinoma: Results of downstaging in patients initially outside the Milan selection criteria. Am J Transpl 8:2547–2557

    Article  CAS  Google Scholar 

  47. Yao FY, Kerlan RK Jr, Hirose R, Davern TJ 3rd, Bass NM, Feng S et al (2008) Excellent outcome following down-staging of hepatocelluar carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 48:819–827

    Article  PubMed  Google Scholar 

  48. Moon DB, Lee SG, Hwang S, Kim KH, Ahn CS, Ha TY et al (2010) The results of living donor liver transplantation for HCC satisfying Milan criteria after down-staging in patients initially outside Milan. Liver Transpl 16:S142 (in abstract)

    Google Scholar 

  49. Monmenti EP, Klintmalm GB (2002) Liver Transplantation in association with hepatocellular carcinoma: an update of the international tumor registry. Liver Transpl 8:736–748

    Article  Google Scholar 

  50. Llovet JM, Bruix J, Fuster J et al (1998) Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. Hepatology 27:1572–1577

    Article  PubMed  CAS  Google Scholar 

  51. Shah SA, Tan JC, McGilvray ID et al (2006) Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma. Transplantation 81:1633–1639

    Article  PubMed  Google Scholar 

  52. Grasso A, Stigliano R, Morisco F et al (2006) Liver transplantation and recurrent hepatocellular carcinoma: predictive value of nodule size in a retrospective and explants study. Transplantation 81:1532–1541

    Article  PubMed  Google Scholar 

  53. Tamura S, Kato T, Berho M et al (2001) Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg 136:25–30

    Article  PubMed  CAS  Google Scholar 

  54. Yao FY, Ferrell I, Bass NM et al (2001) Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33:1394–1403

    Article  PubMed  CAS  Google Scholar 

  55. Regalia E, Fassati LR, Valente U et al (1998) Pattern and management of recurrent hepatocellular carcinoma after liver transplantation. J Hepatobiliary Pancreat Surg 5:29–34

    Article  PubMed  CAS  Google Scholar 

  56. Roayaie S, Schwartz JD, Sung MW et al (2004) Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transplant 10:534–540

    Article  Google Scholar 

  57. Schwartz M, Konstadoulakis M, Roayaie S (2005) Recurrence of hepatocellular carcinoma after liver transplantation: is immunosuppression a factor? LiverTranspl 11:494–496

    Google Scholar 

  58. Yamashiki N, Sugawara Y, Tamura S, Tateishi R, Yoshida H, Kaneko J et al (2010) Postoperative surveillance with monthly serum tumor markers after living-donor liver transplantation for hepatocellular carcinoma. Hepatol Res 40:278–286

    Article  PubMed  Google Scholar 

  59. Hwang S, Ahn CS, Kim KH, Moon DB, Ha TY, Song GW et al (2011) Super-selection of a subgroup of hepatocellular carcinoma patients at minimal risk of recurrence for liver transplantation. J Gastrointest Surg (in print)

    Google Scholar 

  60. Yoon DH, Ryoo BY, Ryu MH, Lee SG, Hwang S, Suh DJ et al (2010) Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Jpn J Clin Oncol 40:768–773

    Article  PubMed  Google Scholar 

  61. Alamo JM, Barrera L, Casado MD, Bernal C, Marin LM, Suarez G et al (2009) Efficacy, tolerance, and safety of mammalian target of rapamycin inhibitors as rescue immunosuppressants in liver transplantation. Transplant Proc 41:2181–2183

    Article  PubMed  CAS  Google Scholar 

  62. Wang Z, Zhou J, Fan J et al (2009) Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma. J Cancer Res Clin Oncol 135:715–722

    Article  PubMed  CAS  Google Scholar 

  63. Toso C, Meeberg GA, Bigam DL et al (2007) De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 83:1162–1168

    Article  PubMed  CAS  Google Scholar 

  64. Yi NJ, Suh KS, Cho JY, Kwon CH, Lee KW, Joh JW et al (2007) Recurrence of hepatitis B is associated with cumulated corticosteroid dose and chemotherapy against hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 13:451–458

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnap-dong, Songpa-gu, Seoul, 138-736, Korea

    Sung-Gyu Lee & Deok-Bog Moon

Authors
  1. Sung-Gyu Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Deok-Bog Moon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sung-Gyu Lee .

Editor information

Editors and Affiliations

  1. M.D. Anderson Cancer Center, Dept. Surgical Oncology, University of Texas, Holcombe Blvd. 1515, Houston, 77030, Texas, USA

    Jean-Nicolas Vauthey

  2. , Dept. of Surgical Oncology, MD Anderson Cancer Center, Holcombe Boulevard, Unit 444 1515, Houston, 77030, USA

    Antoine Brouquet

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Lee, SG., Moon, DB. (2013). Living Donor Liver Transplantation for Hepatocellular Carcinoma. In: Vauthey, JN., Brouquet, A. (eds) Multidisciplinary Treatment of Hepatocellular Carcinoma. Recent Results in Cancer Research, vol 190. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-16037-0_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-16037-0_11

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-16036-3

  • Online ISBN: 978-3-642-16037-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation